Table 3.
Revised original diagnostic scoring system
| Feature | Score | Feature | Score |
|---|---|---|---|
| Gender | Drug history | ||
| Female | 2 | Positive | -4 |
| Male | 0 | Negative | 1 |
| ALP/AST (or ALT) ratio | Average alcohol intake | ||
| <1.5 | 2 | <25 g/day | 2 |
| 1.5–3.0 | 0 | >60 g/day | -2 |
| >3.0 | -2 | Liver histology | |
| Serum globulin or IgG > ULN | Interface hepatitis | 3 | |
| >2.0 | 3 | Lymphoplasmacytic infiltrate | 1 |
| 1.5–2.0 | 2 | Rosetting of hepatocytes | 1 |
| 1.0–1.5 | 1 | None of the above | -5 |
| <1.0 | 0 | Biliary changes | -3 |
| ANA, SMA or LKM-1 (titers) | Other changes | -3 | |
| >1:80 | 3 | Concurrent autoimmune diseases | 2 |
| 1:80 | 2 | Additional findings | |
| 1:40 | 1 | Other defined autoantibodies | 2 |
| <1:40 | 0 | HLA DRB1*03 or DRB1*04 | 1 |
| AMA (+) | -4 | Response to therapy | |
| Hepatitis viral markers | Complete | 2 | |
| Positive | -3 | Relapse | 3 |
| Negative | 3 | ||
| Diagnostic scores | |||
| Pre-treatment score | Post-treatment score | ||
| Definite AIH | >15 | Definite AIH | >17 |
| Probable AIH | 10–15 | Probable AIH | 12–17 |
AIH, autoimmune hepatitis; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AMA, antimitochondrial antibody; ANA, antinuclear antibody; AST, aspartate aminotransferase; HLA, human leukocyte antigen; IgG, immunoglobulin G; LKM-1, antibody to liver kidney microsome type 1; SMA, smooth muscle antibody; ULN, upper limit of normal range.